Antibiotic resistance in Pseudomonas aeruginosa remains one of the most challenging
phenomena of everyday medical science. The universal spread of high-risk clones of …

Pseudomonas aeruginosa is a member of Pseudomonatoda (synonym Proteobacteria)
phylum, belonging to the group of non-fermenting Gram-negative bacteria (NFGNB)(Oren …

Pseudomonas aeruginosa es uno de los principales patógenos que causa infecciones
asociadas a la atención en salud (IAAS). Su capacidad de adaptación, diseminación …

Background Multidrug resistance has become a quandary in the treatment of bacterial
infections. The effect of resistance mutations and the fitness cost on the pathogenicity of …

Trends of rising rates of resistance in Pseudomonas aeruginosa make selection of
appropriate empirical therapy increasingly difficult, but whether multidrug-resistant (MDR) P …

Recent studies have focused on the decreased susceptibility of Pseudomonas aeruginosa
to currently used anti-pseudomonal agents, including β-lactams, aminoglycosides and …

The biological cost of multidrug resistance in Pseudomonas aeruginosa (PA) remains
unclear. This study aimed to evaluate the relationship between pathogenicity and the …

Multidrug-resistant (MDR) Pseudomonas aeruginosa represents a major clinical concern.
The interplay between antimicrobial resistance and virulence of P. aeruginosa was …

Pseudomonas aeruginosa is one of the leading nosocomial pathogens worldwide.
Nosocomial infections caused by this organism are often hard to treat because of both the …

Abstract Objectives Carbapenem-resistant Pseudomonas aeruginosa are emerging
worldwide with increasing reports of carbapenemase-producing isolates. Carbapenem …